Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Rexahn Pharmaceuticals to Present at the Biopharm America(TM) 2015 Conference in Boston

GlobeNewswire September 8, 2015

Rexahn Pharmaceuticals to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 10, 2015

GlobeNewswire August 31, 2015

Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2015

Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

GlobeNewswire July 14, 2015

Rexahn Announces the Appointment of Peter Brandt as Chairman of the Board

GlobeNewswire June 22, 2015

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

GlobeNewswire June 9, 2015

National Cancer Institute Accepts Rexahn's RX-21101 for Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program

GlobeNewswire June 8, 2015

Rexahn Announces Poster Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 13, 2015

Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results and Pipeline Update

GlobeNewswire May 11, 2015

New Data Show Rexahn's Supinoxin(TM) Decreases the Migration of Human Triple Negative Breast Cancer Cells in a Metastatic Cancer Model

GlobeNewswire April 21, 2015

Rexahn Pharmaceuticals to Present Data on RX-3117 and Supinoxin(TM) at the 2015 American Association for Cancer Research Annual Meeting

GlobeNewswire April 13, 2015

Rexahn Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference in Tokyo, Japan

GlobeNewswire March 18, 2015

Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update

GlobeNewswire March 17, 2015

Rexahn Pharmaceuticals to Present at the BIO-Europe Spring(R) 2015 Conference in Paris, France

GlobeNewswire March 4, 2015

Rexahn Pharmaceuticals to Present at the ROTH Capital Partners 27th Annual Growth Stock Conference

GlobeNewswire March 2, 2015

Rexahn Pharmaceuticals to Present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum in New York

GlobeNewswire February 18, 2015

Rexahn Pharmaceuticals Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action

GlobeNewswire February 9, 2015

Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer

GlobeNewswire February 4, 2015

Rexahn Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference

GlobeNewswire February 2, 2015

Rexahn Pharmaceuticals to Present at Biotech Showcase(TM) 2015

GlobeNewswire January 7, 2015